A replacement for warfarin: The search continues

Circulation

Volumn 116, Issue 2, 2007, Pages 131-133

  Eikelboom, John W ^a   Weitz, Jeffrey I ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Anticoagulants; Editorials; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING DISORDER; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG WITHDRAWAL; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LIVER TOXICITY; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; SECONDARY PREVENTION; SIDE EFFECT; STROKE; SURGICAL PATIENT; THERAPY EFFECT; THROMBOSIS PREVENTION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CLINICAL TRIALS, PHASE II; FACTOR XA; HUMANS; MORPHOLINES; THIOPHENES; THROMBOSIS; VITAMIN K; WARFARIN;

EID: 34447338638     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.712349     Document Type: Editorial

References (15)

1. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865-1875.
2. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol. 2006;134:3-19.
3. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost. 2006;96:274-284.
4. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27:1238-1247.
5. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M, for the ODIXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost. 2005;3:2479-2486.
6. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P, for the ODIXa-HIP Study Investigators. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121-128.
7. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P, for the ODIXa-HIP Study Investigators. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-2381.
8. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, for the ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-187.
9. Buller HR, for the EISTEIN-DVT Study Group. Once daily treatment with an oral, direct factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis: the EINSTEIN-DVT doseranging study. Eur Heart J. 2006;27:761. Abstract.
10. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, for the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
11. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.
12. Hull RD, Marder VJ, Mah AF, Biel RK, Brant RF. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med. 2005;118:456-464.
13. Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation. 2000;102:2726-2731.
14. PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost. 2004;2:47-53.
15. Eriksson BI, Dahl OE, van Dijk CN, Frostick SP, Kurth AA, Rosencher N, Schnee J, Hettiarachchi R, Christiansen AY, Hantel S, Büller HR. A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (the RE-MODEL Trial). Blood. 2006;108:573. Abstract.